Trial Information
Multicenter Prospective Evaluation of Patient- and Lesion Specific Prognostic Factors for Standard RadioImmunoTherapy With 90-Yttrium-labeled Anti-CD20 in Follicular Non-Hodgkin´s Lymphoma
Inclusion Criteria:
- standard radioimmunotherapy with 90-yttrium-labeled anti-CD20-antibodies in
treatment of relapsed and/or refractory follicular NHL or partial remission after
induction chemotherapy
- finding of at least one image-guided measurable lymphoma lesion
- existence of FDG-PET- and CT-image data of at most 8 weeks before treatment
- signed patient´s agreement for RIT registry and MERIT-NHL
Exclusion Criteria:
- other therapy modalities than standard radioimmunotherapy (e.g. consolidation)
- solely CNS-lymphoma or primary effusion lymphoma
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Outcome Measure:
Evaluation of patient- and lesion specific prognostic factors of radioimmunotherapy
Outcome Time Frame:
3 years
Safety Issue:
No
Principal Investigator
Carl-Martin Kirsch, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Universitaetsklinikum des Saarlandes
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
MERIT-NHL
NCT ID:
NCT01151358
Start Date:
May 2008
Completion Date:
December 2011
Related Keywords:
- Follicular Lymphoma
- radioimmunotherapy
- follicular non-Hodgkin´s lymphoma
- FDG-PET
- prognostic factors
- multicenter study
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin